Bone density measurement is a critical tool in the management of glucocorticoid-induced osteoporosis (GIOP). This review addresses the utility of various measurement devices (dual-energy X-ray absorptiometry [DXA], quantitative ultrasound [QUS], quantitative CAT scanning [QCT]), their role in monitoring changes in bone mineral density (BMD), and the relationship of BMD and fracture risk in GIOP. A higher BMD threshold should be utilized for estimating fracture risk in patients on glucocorticoids.